The NEMO (NEuroMuscular Omniservice) Clinical Center, Milan, Italy.
Neurorehabilitation Unit, University of Milan, Milan, Italy.
Can Respir J. 2022 Jun 18;2022:2321909. doi: 10.1155/2022/2321909. eCollection 2022.
Respiratory insufficiency is one of the main causes of death in myotonic dystrophy type 1 (DM1). Although there is general consensus that these patients have a restrictive ventilatory pattern, hypoventilation, chronic hypercapnia, and sleep disturbances, the prevalence of respiratory disease and indication for the effects of noninvasive ventilation (NIV) need to be further explored.
To describe respiratory function and need for NIV at baseline and over time in a cohort of adult patients with DM1.
A total of 151 adult patients with DM1 were subjected to arterial blood gas analysis, sitting and supine forced vital capacity (FVC), peak cough expiratory flow (PCEF), nocturnal oximetry, and maximal inspiratory pressure and expiratory pressure (MIP/PEP).
On first assessment, 84 of 151 had normal respiratory function (median age: 38 years, median BMI: 23.9, and median disease duration: 11 years); 67 received an indication to use NIV (median age: 49 years, median BMI: 25,8, and median disease duration: 14 years). After a median time of 3.85 years, 43 patients were lost to follow-up; 9 of 84 required NIV; only 17 of 67 with the new NIV prescription were adherent.
We provide additional data on the natural history of respiratory function decline and treatment adherence in a relatively large cohort of well-characterized patients with DM1. A high proportion (28%) was lost to follow-up. A minority (11%) required NIV, and only 25% were treatment adherent, irrespective of specific demographics and respiratory features. Our results also confirm previous findings, showing that age, disease duration, and higher BMIs are predisposing factors for respiratory impairment.
呼吸功能不全是 1 型肌强直性营养不良(DM1)患者死亡的主要原因之一。尽管普遍认为这些患者存在限制性通气模式、低通气、慢性高碳酸血症和睡眠障碍,但仍需进一步探讨呼吸疾病的患病率和无创通气(NIV)的适应证。
描述一组成年 DM1 患者的基线和随时间变化的呼吸功能及 NIV 需求。
共对 151 例成年 DM1 患者进行动脉血气分析、坐位和仰卧位用力肺活量(FVC)、最大咳嗽呼气流量(PCEF)、夜间血氧饱和度和最大吸气压力及呼气压力(MIP/PEP)检测。
首次评估时,151 例患者中有 84 例呼吸功能正常(中位年龄:38 岁,中位 BMI:23.9,中位病程:11 年);67 例患者需要使用 NIV(中位年龄:49 岁,中位 BMI:25.8,中位病程:14 年)。中位随访时间为 3.85 年后,43 例患者失访;84 例需要 NIV 的患者中有 9 例接受了 NIV;67 例新处方 NIV 的患者中只有 17 例依从治疗。
我们在一组特征明确的较大 DM1 患者队列中提供了关于呼吸功能下降和治疗依从性的自然史的额外数据。失访率较高(28%)。仅有少数(11%)患者需要 NIV,无论具体的人口统计学和呼吸特征如何,仅有 25%的患者依从治疗。我们的结果也证实了先前的发现,表明年龄、病程和更高的 BMI 是呼吸损害的易患因素。